美国国立综合癌症网络（NCCN）指南见解：B细胞淋巴瘤，2021年第5版
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
作者信息
Zelenetz Andrew D, Gordon Leo I, Chang Julie E, Christian Beth, Abramson Jeremy S, Advani Ranjana H, Bartlett Nancy L, Budde L Elizabeth, Caimi Paolo F, De Vos Sven, Dholaria Bhagirathbhai, Fakhri Bita, Fayad Luis E, Glenn Martha J, Habermann Thomas M, Hernandez-Ilizaliturri Francisco, Hsi Eric, Hu Boyu, Kaminski Mark S, Kelsey Christopher R, Khan Nadia, Krivacic Susan, LaCasce Ann S, Lim Megan, Narkhede Mayur, Rabinovitch Rachel, Ramakrishnan Praveen, Reid Erin, Roberts Kenneth B, Saeed Hayder, Smith Stephen D, Svoboda Jakub, Swinnen Lode J, Tuscano Joseph, Vose Julie M, Dwyer Mary A, Sundar Hema
机构信息
Memorial Sloan Kettering Cancer Center.
Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
出版信息
J Natl Compr Canc Netw. 2021 Nov;19(11):1218-1230. doi: 10.6004/jnccn.2021.0054.
In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody-drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1-mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.
在过去十年中，对B细胞非霍奇金淋巴瘤分子发病机制的更深入了解促使了新型靶向疗法的发展，例如B细胞受体途径中特定激酶的小分子抑制剂、抗体药物偶联物以及靶向多种蛋白质（如CD-19、EZH2和XPO-1介导的核输出）的小分子。抗CD19嵌合抗原受体T细胞疗法最初被批准用于复发/难治性（R/R）弥漫性大B细胞淋巴瘤，如今也已成为R/R滤泡性淋巴瘤和套细胞淋巴瘤的一种新型治疗选择。这些美国国立综合癌症网络（NCCN）指南见解强调了NCCN B细胞淋巴瘤指南中包含的用于治疗R/R疾病的新靶向治疗选择。
Zotero 插件